Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.
Circulation
; 150(3): 171-173, 2024 Jul 16.
Article
em En
| MEDLINE
| ID: mdl-39008562
ABSTRACT
Our research investigates the societal implications of access to glucagon-like peptide-1 (GLP-1) agonists, particularly in light of recent clinical trials demonstrating the efficacy of semaglutide in reducing cardiovascular mortality. A decade-long analysis of Google Trends indicates a significant increase in searches for GLP-1 agonists, primarily in North America. This trend contrasts with the global prevalence of obesity. Given the high cost of GLP-1 agonists, a critical question arises Will this disparity in medication accessibility exacerbate the global health equity gap in obesity treatment? This viewpoint explores strategies to address the health equity gap exacerbated by this emerging medication. Because GLP-1 agonists hold the potential to become a cornerstone in obesity treatment, ensuring equitable access is a pressing public health concern.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Equidade em Saúde
/
Receptor do Peptídeo Semelhante ao Glucagon 1
/
Obesidade
Limite:
Humans
Idioma:
En
Revista:
Circulation
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Canadá